Literature DB >> 26892990

Screening Out Controversy: Human Genetics, Emerging Techniques of Diagnosis, and the Origins of the Social Issues Committee of the American Society of Human Genetics, 1964-1973.

M X Mitchell1,2.   

Abstract

In the years following World War II, and increasingly during the 1960s and 1970s, professional scientific societies developed internal sub-committees to address the social implications of their scientific expertise (Moore, Disrupting Science: Social Movements, American Scientists, and the Politics of the Military, 1945-1975. Princeton: Princeton University Press, 2008). This article explores the early years of one such committee, the American Society of Human Genetics' "Social Issues Committee," founded in 1967. Although the committee's name might suggest it was founded to increase the ASHG's public and policy engagement, exploration of the committee's early years reveals a more complicated reality. Affronted by legislators' recent unwillingness to seek the expert advice of human geneticists before adopting widespread neonatal screening programs for phenylketonuria (PKU), and feeling pressed to establish their relevance in an increasingly resource-scarce funding environment, committee members sought to increase the discipline's expert authority. Painfully aware of controversy over abortion rights and haunted by the taint of the discipline's eugenic past, however, the committee proceeded with great caution. Seeking to harness interest in and assert professional control over emerging techniques of genetic diagnosis, the committee strove to protect the society's image by relegating ethical and policy questions about their use to the individual consciences of member scientists. It was not until 1973, after the committee's modest success in organizing support for a retrospective public health study of PKU screening and following the legalization of abortion on demand, that the committee decided to take a more publicly engaged stance.

Entities:  

Keywords:  Abortion; Bioethics; Boundary-work; Democratization of science; Eugenics; Genetic screening; Human genetics; Prenatal diagnosis

Mesh:

Year:  2017        PMID: 26892990     DOI: 10.1007/s10739-016-9437-8

Source DB:  PubMed          Journal:  J Hist Biol        ISSN: 0022-5010            Impact factor:   1.326


  13 in total

1.  2001 William Allan Award Address. From Down syndrome to the "human" in "human genetics".

Authors:  Charles J Epstein
Journal:  Am J Hum Genet       Date:  2001-12-26       Impact factor: 11.025

2.  Organizing integrity: American science and the creation of public interest organizations, 1955-1975.

Authors:  K Moore
Journal:  AJS       Date:  1996-05

3.  The origins of the neutral theory of molecular evolution.

Authors:  M R Dietrich
Journal:  J Hist Biol       Date:  1994       Impact factor: 1.326

4.  What does it mean to go public? The American response to Lysenkoism, reconsidered.

Authors:  Audra J Wolfe
Journal:  Hist Stud Nat Sci       Date:  2010       Impact factor: 1.162

5.  Progress and prospects in human genetics.

Authors:  H J Muller
Journal:  Am J Hum Genet       Date:  1949-09       Impact factor: 11.025

6.  Our load of mutations.

Authors:  H J MULLER
Journal:  Am J Hum Genet       Date:  1950-06       Impact factor: 11.025

7.  How lysenkoism became pseudoscience: dobzhansky to velikovsky.

Authors:  Michael D Gordin
Journal:  J Hist Biol       Date:  2012       Impact factor: 1.326

8.  Our twenty-fifth.

Authors:  J V Neel
Journal:  Am J Hum Genet       Date:  1974-03       Impact factor: 11.025

9.  The William Allan Memorial Award Lecture. On the nature of men.

Authors:  J Lejeune
Journal:  Am J Hum Genet       Date:  1970-03       Impact factor: 11.025

10.  A geneticist looks at contraception and abortion.

Authors:  J Lederberg
Journal:  Ann Intern Med       Date:  1967-09       Impact factor: 25.391

View more
  1 in total

1.  Framing utility: Regulatory reform and genetic tests in the USA, 1989-2000.

Authors:  Steve Sturdy
Journal:  Soc Sci Med       Date:  2020-03-19       Impact factor: 5.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.